Compare Western Union Co (WU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Union Co vs State Street SPDR S&P Biotech ETF — how do they compare? Western Union Co trades at $6.14 (market cap $1.97B), while State Street SPDR S&P Biotech ETF trades at $154.35 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 5.1× Western Union Co's market cap, and Western Union Co pays a 14.85% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Western Union Co for 95 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| WU | XBI | |
|---|---|---|
Market Cap | $1.97B | $10.11B |
Volume | 10,235,212 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $10.28 | $169.55 |
52-Week Low | $5.90 | $104.99 |
Typical Hold Time | 95 Days | 37 Days |
Enterprise Value | $1.88B | — |
Dividend Yield | 14.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Western Union (WU) trades at $6.145, up 0.57% on the day, with a mixed technical signal leaning bearish in moving averages but bullish overall. The company shows strong profitability with a 43.97% ROE and a net income margin of 9.79%, though revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent earnings have missed expectations in Q1 and Q2 2026, while the pending Intermex acquisition and a $200M cost-cutting plan aim to bolster future performance amid competitive pressures.
The stock presents a value opportunity with low P/E (5.1) and P/S (0.5) ratios, supported by a consensus price target of $6.86 offering ~12% upside. However, risks include earnings volatility, regulatory hurdles for the Intermex deal, and declining revenue trends. Analyst sentiment is cautious with only 12% buy ratings, suggesting a hold stance may be prudent until earnings stabilize and strategic initiatives show clearer results.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
